AtaiBeckley Inc. (ATAI) Form 8-K — Sep 11, 2026
AtaiBeckley Inc. completed its merger with Eli Lilly and Company on September 11, 2026, with the company surviving as a wholly owned Lilly subsidiary under the merger agreement dated July 15, 2026. Each share of ATAI common stock was converted into the right to receive $6.75 in cash plus one contingent value right worth up to $2.50, payable on milestones including a VLS-01 Phase 3 trial start and FDA approval plus DEA rescheduling of BPL-003 and VLS-01. ATAI common stock is being delisted from Nasdaq: the company requested trading suspension and a Form 25 deregistration, with a Form 15 to follow ending SEC reporting obligations.
Key figures
- Closing date
- 2026-09-11
- Cvr max per share usd
- 2.5
- Merger agreement date
- 2026-07-15
- Closing amount per share usd
- 6.75
- Cvr milestone vls01 deadline
- prior to 7th anniversary of Closing Date
- Max total consideration note
- derived: $6.75 cash + up to $2.50 CVR
- Cvr milestone bpl003 deadline
- prior to 5th anniversary of Closing Date
- Retention bonus kochendoerfer usd
- 194000
- Cvr milestone vls01 phase3 deadline
- prior to 4th anniversary of Closing Date
- Cvr milestone vls01 phase3 initiation usd
- 1
- Cvr milestone vls01 approval and dea rescheduling usd
- 1
- Cvr milestone bpl003 approval and dea rescheduling usd
- 0.5
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.